NFKB1 and breast carcinoma: Previous investigation demonstrated that CMTM1_v17 expressed in various types of solid tumors (breast cancer, kidney cancer, lung cancer, liver cancer, and ovarian cancer) and could promote the proliferation and lead to partial resistance to tumor necrosis factor-α (TNF-α) induced apoptosis via activation of NF-κB signaling pathway in breast cancer [11].